SCHEMBL2583438

SCHEMBL2583438

Cc1cn2nccc(N3CCOCC3)c2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 6/20 0.52
NCF1 P14598 1/20 0.47
HPGD P15428 1/20 0.44
ACVR1 Q04771 1/20 0.44
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PIK3CA P42336 2/20 0.42
PIK3R1 P27986 1/20 0.42
PDE2A O00408 1/20 0.42
PDE8A O60658 1/20 0.42
PDE5A O76074 1/20 0.42
PDE9A O76083 1/20 0.42
PDE6A P16499 1/20 0.42
HTR2C P28335 1/20 0.42
HTR7 P34969 1/20 0.42
HTR2B P41595 1/20 0.42
PDE1B Q01064 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2575400 0.81 PDE10A (0.49) PDE10ANCF1NPC1RAB9AMAPT
SCHEMBL2575429 0.79 SMPD3 (0.52) PDE10ANCF1HPGDKDM4EMAPT
SCHEMBL16283760 0.78 PDE10A (0.54) PDE10ANCF1MAPTPDE2APDE8A
SCHEMBL2575482 0.78 PDE10A (0.61) PDE10AMAPTPIK3CAPIK3R1GSK3A
SCHEMBL16278808 0.78 PDE10A (0.49) PDE10AMAPTPIK3CAPIK3R1PDE2A
SCHEMBL16278645 0.78 PDE10A (0.57) PDE10ANPC1RAB9AMAPTPDE2A
SCHEMBL30627468 0.78 IRAK4 (0.48) NCF1HPGDNPC1RAB9AKDM4E
SCHEMBL31519311 0.77 PDE10A (0.56) PDE10AMAPTPIK3CAPDE2APDE8A
SCHEMBL16283750 0.77 PDE10A (0.56) PDE10ANCF1HPGDKDM4EMAPT
SCHEMBL2585764 0.76 SMPD3 (0.47) PDE10ANPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493889-B1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-06 EP disclosed
EP-2493889-B1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-06 EP disclosed
US-9550784-B2 Inhibitors of phosphodiesterase 10 enzyme Beerse Pharmaceutica NV (BE) 2017-01-24 US disclosed
US-9550784-B2 Inhibitors of phosphodiesterase 10 enzyme Beerse Pharmaceutica NV (BE) 2017-01-24 US disclosed
EP-2869822-B1 INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME JANSSEN PHARMACEUTICA NV (BE) 2016-09-14 EP disclosed
US-9193736-B2 PDE 10a inhibitors for the treatment of type II diabetes JANSSEN PHARMACEUTICA, NV (BE) 2015-11-24 US disclosed
US-20150203498-A1 INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME JANSSEN PHARMACEUTICA NV (BE) 2015-07-23 US disclosed
US-20150203498-A1 INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME JANSSEN PHARMACEUTICA NV (BE) 2015-07-23 US disclosed
US-20140364413-A1 PDE 10a Inhibitors for the Treatment of Type II Diabetes JANSSEN PHARMACEUTICA, NV (BE) 2014-12-11 US disclosed
US-8716282-B2 Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-05-06 US disclosed
WO-2014009305-A1 INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME JANSSEN PHARMACEUTICA NV (BE) 2014-01-16 WO disclosed
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN-CILAG, S.A. (ES) 2012-08-30 US disclosed
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN-CILAG, S.A. (ES) 2012-08-30 US disclosed
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN-CILAG, S.A. (ES) 2012-08-30 US disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 US disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 US disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 US disclosed
WO-2011051342-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364413-A1 PDE 10a Inhibitors for the Treatment of Type II Diabetes PDE2A, PDE3B, PDE3A PDE10A 9/4885NCF1 3359/4885HPGD 506/4885
US-20150203498-A1 INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME PDE12, PDE5A, PDE2A PDE10A 5/4885NCF1 3459/4885HPGD 175/4885
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PDE12, PDE10A, PDE5A PDE10A 2/4885NCF1 3969/4885HPGD 373/4885
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PDE12, PDE10A, PDE5A PDE10A 2/4885NCF1 3969/4885HPGD 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.